JP2024517871A5 - - Google Patents

Info

Publication number
JP2024517871A5
JP2024517871A5 JP2023568310A JP2023568310A JP2024517871A5 JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5 JP 2023568310 A JP2023568310 A JP 2023568310A JP 2023568310 A JP2023568310 A JP 2023568310A JP 2024517871 A5 JP2024517871 A5 JP 2024517871A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
optionally
amino acid
sequence identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517871A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/072121 external-priority patent/WO2022236292A2/en
Publication of JP2024517871A publication Critical patent/JP2024517871A/ja
Publication of JP2024517871A5 publication Critical patent/JP2024517871A5/ja
Pending legal-status Critical Current

Links

JP2023568310A 2021-05-07 2022-05-05 プロテアーゼ活性化治療剤を含む組成物および方法 Pending JP2024517871A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163185941P 2021-05-07 2021-05-07
US63/185,941 2021-05-07
US202263313087P 2022-02-23 2022-02-23
US63/313,087 2022-02-23
PCT/US2022/072121 WO2022236292A2 (en) 2021-05-07 2022-05-05 Compositions and methods comprising protease-activated therapeutic agents

Publications (2)

Publication Number Publication Date
JP2024517871A JP2024517871A (ja) 2024-04-23
JP2024517871A5 true JP2024517871A5 (enExample) 2025-05-15

Family

ID=83932456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568310A Pending JP2024517871A (ja) 2021-05-07 2022-05-05 プロテアーゼ活性化治療剤を含む組成物および方法

Country Status (4)

Country Link
US (1) US20240228586A1 (enExample)
EP (1) EP4333873A4 (enExample)
JP (1) JP2024517871A (enExample)
WO (1) WO2022236292A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
IL293978A (en) 2019-12-20 2022-08-01 Regeneron Pharma New il2 agonists and methods of using them
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024153768A1 (en) * 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009221976B2 (en) * 2008-03-03 2014-02-27 Kansas State University Research Foundation Protease assay
WO2016023040A1 (en) * 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs

Similar Documents

Publication Publication Date Title
JP2022542886A5 (enExample)
US9796777B2 (en) Methods of treating malignant tumors
CN113226472A (zh) 双免疫细胞衔接物
JP7848182B2 (ja) 改善された抗原結合受容体
CA2289912A1 (en) Human receptor proteins; related reagents and methods
CA2386463A1 (en) April receptor (bcma) and uses thereof
US20220098274A1 (en) Engineered pd-1 variants
CA2561826A1 (en) Linear single chain recombinant anti-cea/cd3/cd28 trispecific antibody
WO2021092075A1 (en) IL-2RβγC BINDING COMPOUNDS
JP2020508691A5 (enExample)
CN110461360A (zh) 改进的抗原结合受体形式
JP2023547447A (ja) 改良型抗原結合受容体
RU2010121967A (ru) Белковые каркасные структуры
KR20220093323A (ko) HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
KR20240111753A (ko) 개선된 항원 결합 수용체
JP2022535816A5 (enExample)
US20260103528A1 (en) Nanobodies that bind to gprc5d and uses thereof
JP2026048706A5 (enExample)
KR101974583B1 (ko) 링커 폴리펩티드 및 이를 이용한 표적 물질 분석 방법
AU2024401183A1 (en) Novel serum albumin-binding fusion proteins
WO2024003393A1 (en) Fusion proteins with half life extending domains
CN119731199A (zh) 工程化的白细胞介素-2受体β降低结合的激动剂
HK40113187A (en) Improved antigen binding receptors
JP2025527694A5 (enExample)
WO2025080338A1 (en) Cell-surface anchored cytokine therapy